<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">15814336</PMID>
        <DateCompleted>
            <Year>2005</Year>
            <Month>06</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0925-5710</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>81</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of hematology</Title>
                <ISOAbbreviation>Int. J. Hematol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>246-54</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In treating elderly non-Hodgkin's lymphoma (NHL) patients, it is particularly important to use drugs that have a low incidence of adverse events and high efficacy. In this multicenter study, THP (pirarubicin)-COP (cyclophosphamide, vincristine, and prednisolone) was compared to two thirds dosage of full CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen with regard to both adverse events and efficacy. For a third group, etoposide (E) was added to the THP-COP regimen (THP-COPE) in order to achieve high dose-intensity. Subjects were 486 previously untreated patients, aged 65 or older (range, 65-92 years; median, 74 years), with NHL. Subjects were randomly assigned to receive THP-COP, two thirds CHOP, or THP-COPE. Four hundred and forty-three patients were assessed for response and followed for 8 years after the last subject registered. The complete remission rates for the THP-COP, CHOP, and THP-COPE groups were 42.5%, 41.4%, and 48.0%, respectively. There was no difference in overall survival or progression-free survival among these 3 groups. In aggressive lymphoma, there was also no difference in complete response (CR) rate (45.3% in THP-COP, 44.9% in CHOP, 48.0% in THP-COPE), overall survival, and progression-free survival among these groups. The 5- and 8-year survival rates for all patients were 29.4% and 18.7%, respectively. The 5- and 8-year survival rates for patients with aggressive lymphoma were 27.4% and 17.4%, respectively. Although long-term survival for patients with aggressive lymphoma on our regimens was not worse compared to previous reports, the CR rate was lower. Because severe adverse events were not observed, higher dose chemotherapy may be directed to achieve better CR rates. In patients with T-cell-type lymphoma, the CR rate was greater after treatment with THP-COP (51.4%) or THP-COPE (57.7%) compared to treatment with CHOP (19.4%). Pirarubicin may be more useful for T-cell lymphoma than doxorubicin. Because adverse cardiac events were reported only in CHOP, adverse cardiac events might be low in the THP group.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mori</LastName>
                    <ForeName>Mayumi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology, Tokyo Metropolitan Geriatric Hospital, Japan. blut@tmgh.metro.tokyo.jp</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kitamura</LastName>
                    <ForeName>Kiyoshi</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masuda</LastName>
                    <ForeName>Michihiko</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hotta</LastName>
                    <ForeName>Tomomitsu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miyazaki</LastName>
                    <ForeName>Tamotsu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miura</LastName>
                    <ForeName>Akira B</ForeName>
                    <Initials>AB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mizoguchi</LastName>
                    <ForeName>Hideaki</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shibata</LastName>
                    <ForeName>Akira</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saito</LastName>
                    <ForeName>Hidehiko</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsuda</LastName>
                    <ForeName>Tamotsu</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Masaoka</LastName>
                    <ForeName>Toru</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harada</LastName>
                    <ForeName>Mine</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Niho</LastName>
                    <ForeName>Yoshiyuki</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takaku</LastName>
                    <ForeName>Fumimaro</ForeName>
                    <Initials>F</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Int J Hematol</MedlineTA>
            <NlmUniqueID>9111627</NlmUniqueID>
            <ISSNLinking>0925-5710</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>5J49Q6B70F</RegistryNumber>
                <NameOfSubstance UI="D014750">Vincristine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8N3DW7272P</RegistryNumber>
                <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9PHQ9Y1OLM</RegistryNumber>
                <NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>VB0R961HZT</RegistryNumber>
                <NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <SupplMeshList>
            <SupplMeshName Type="Protocol" UI="C034587">CHOP protocol</SupplMeshName>
            <SupplMeshName Type="Protocol" UI="C062938">VEP-THP protocol</SupplMeshName>
        </SupplMeshList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008228" MajorTopicYN="N">Lymphoma, Non-Hodgkin</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014750" MajorTopicYN="N">Vincristine</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>17</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">15814336</ArticleId>
            <ArticleId IdType="pii">XA66W8YULW12BF3H</ArticleId>
            <ArticleId IdType="doi">10.1532/IJH97.03147</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 1993 Sep 30;329(14 ):987-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8141877</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 1998 Nov;9(11):1219-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9862053</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1983 Dec 1;52(11):1986-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6354419</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 1994;5 Suppl 1:19-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8172811</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2004 Aug 1;104(3):634-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15016643</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Haematologica. 1998 Mar;83(3):217-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9573675</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 1997 Oct;8(10):973-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9402170</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leuk Lymphoma. 1996 Aug;22(5-6):483-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8882962</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leuk Lymphoma. 2001 Apr;41(3-4):359-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11378549</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 1992;28A(10):1670-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1389483</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1995 Jan 1;75(1 Suppl):370-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8001008</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 1977 Jan;35(1):1-39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">831755</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1997 Aug;15(8):2945-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9256139</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leukemia. 1997 Nov;11(11):1817-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9369412</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biometrika. 1965 Jun;52:203-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14341275</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1976 Oct;38(4):1484-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">791473</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1986 Mar;4(3):295-305</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3512783</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Hematol. 2002 Dec;76(5):385-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12512832</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2003 May 15;101(10):3840-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12531794</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 1998 Jul 1;92(1):76-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9639502</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Acta Oncol. 1995;34(1):87-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7865241</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leuk Lymphoma. 1998 Aug;30(5-6):591-600</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9711921</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Important Adv Oncol. 1988;:121-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3042601</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 1992 Dec;3(10):833-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1286045</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hematol Oncol. 1987 Apr-Jun;5(2):127-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2439430</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 1999 Jul 1;94(1):33-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10381495</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 1994;30A(9):1337-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7999422</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1993 Dec;11(12):2362-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7504091</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leuk Lymphoma. 2001 Feb;40(5-6):529-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11426526</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2003 Jun 1;21(11):2115-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12775737</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 2002 Jan 15;136(2):144-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11790067</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2003 Dec 15;102(13):4284-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12920037</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Am Geriatr Soc. 1984 Apr;32(4):269-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6368652</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1991 Mar 15;67(6):1487-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1705861</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1995 Oct;13(10):2530-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7595704</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1991 May;9(5):741-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1707954</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Acta Oncol. 1990;29(6):733-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2223144</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Oncol. 2001 Aug;24(4):360-2</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11474261</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1998 Jul;16(7):2352-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9667250</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1991 Feb;9(2):339-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1824863</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1993 Nov;11(11):2250-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8229141</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leuk Lymphoma. 2003 Jun;44(6):967-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12854895</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2003 Feb;14(2):258-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12562653</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2002 Jan 24;346(4):235-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11807147</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1998 Jan;16(1):27-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9440719</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 1996 Nov;7(9):966-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9006749</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2003 Jan 1;21(1):5-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12506163</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2001 May 15;97(10):2991-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11342422</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leuk Lymphoma. 1995 Jun;18(1-2):145-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8580817</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Hematol. 1998 Oct;59(2):156-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9766801</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2003 Aug 15;21(16):3041-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12915593</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Invest. 1990;8(6):577-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2292050</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>